Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines

Omar M. Albalawi, Maha I. Alomran, Ghada M. Alsagri, Turki A. Althunian, Thamir M. Alshammari
doi: https://doi.org/10.1101/2021.07.10.21260304

Article Information

doi 
https://doi.org/10.1101/2021.07.10.21260304
History 
  • July 12, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Omar M. Albalawi, MPH1,
  2. Maha I. Alomran, BSc, MSc1,
  3. Ghada M. Alsagri, BSc1,
  4. Turki A. Althunian, PhD1 and
  5. Thamir M. Alshammari, BPharm, PhD1,2,3,*
  1. 1Executive Directorate for Research and Studies, Saudi Food and Drug Authority, Riyadh, Saudi Arabia
  2. 2College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia
  3. 3Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia
  1. ↵* Corresponding author; email: thamer.alshammary{at}gmail.com
Back to top
Posted July 12, 2021.
Download PDF
Data/Code
Email
Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
Omar M. Albalawi, Maha I. Alomran, Ghada M. Alsagri, Turki A. Althunian, Thamir M. Alshammari
medRxiv 2021.07.10.21260304; doi: https://doi.org/10.1101/2021.07.10.21260304
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area